Unique ID issued by UMIN | UMIN000045469 |
---|---|
Receipt number | R000051912 |
Scientific Title | Randomized, double-blind, placebo-controlled parallel-group comparative study to evaluate the efficacy in probiotics on maintaining physical condition |
Date of disclosure of the study information | 2021/09/14 |
Last modified on | 2023/03/20 14:37:45 |
Randomized, double-blind, placebo-controlled parallel-group comparative study to evaluate the efficacy in probiotics on maintaining physical condition
Clinical study to evaluate the efficacy in probiotics on maintaining physical condition
Randomized, double-blind, placebo-controlled parallel-group comparative study to evaluate the efficacy in probiotics on maintaining physical condition
Clinical study to evaluate the efficacy in probiotics on maintaining physical condition
Japan |
None
Not applicable | Adult |
Others
NO
The aim of this study is to evaluate the effect of Probiotics on maintaining physical condition among healthy adults.
Efficacy
Subjective symptoms of physical conditions
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Prevention
Food |
Intake of powdered probiotic for 12 weeks
Intake of powdered placebo for 12 weeks
20 | years-old | <= |
75 | years-old | > |
Male and Female
1) Subjects of both sexes aged 20 years or older and younger than 75 years.
1) Subjects who have disease or serious medical history in liver, kidney, heart, lung, gastrointestinal tract, blood, endocrine system, or metabolism, etc.
2) Subjects who regularly use oral or nasal medications
3) Subjects with severe perennial or seasonal allergic symptoms (those who develop symptoms during this study period and take steroids)
4) Subjects who are scheduled to be vaccinated against COVID-19 from two weeks before the start of this study to the end of this study
5) Subjects with serious medication allergy, food allergy, or history of these
6) Subjects who are pregnant, under lactation or expecting to be pregnant during this study
7) Subjects who participated in other study within 1 month prior to obtaining informed consent
8) Any candidates considered to be inappropriate for this study by the principal investigator based on their background, physical examination, etc.
200
1st name | Nakamura |
Middle name | |
Last name | Masahiko |
Matsumoto City Hospital
hospital director
390-1401
4417-180 Hata, Matsumoto-shi, Nagano-ken, 390-1401, Japan
0263-92-3027
hospi@city.matsumoto.lg.jp
1st name | Shimamura |
Middle name | |
Last name | Akira |
Matsumoto Health Lab
None
390-0811
M wing 1F, 1-18-1, Chuo, Matsumoto, Nagano, Japan
0263-39-1139
info@m-health-lab.jp
Matsumoto City Hospital
Morinaga Milk Industry Co., Ltd.
Profit organization
Research Ethics Committee of Matsumoto City Hospital
4417-180 Hata, Matsumoto-shi, Nagano-ken, 390-1401, Japan
0263-92-3027
hospi@city.matsumoto.lg.jp
NO
2021 | Year | 09 | Month | 14 | Day |
Unpublished
200
Completed
2021 | Year | 08 | Month | 13 | Day |
2021 | Year | 08 | Month | 24 | Day |
2021 | Year | 09 | Month | 14 | Day |
2022 | Year | 02 | Month | 19 | Day |
2021 | Year | 09 | Month | 13 | Day |
2023 | Year | 03 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051912
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |